ABLYNX (OTCMKTS:ABLYF) is scheduled to post its quarterly earnings results after the market closes on Thursday, February 22nd. Analysts expect ABLYNX to post earnings of ($0.21) per share for the quarter.
Shares of ABLYNX (OTCMKTS:ABLYF) opened at $53.85 on Thursday. ABLYNX has a 52-week low of $11.10 and a 52-week high of $54.75.
A number of analysts recently issued reports on the company. ValuEngine raised ABLYNX from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research raised ABLYNX from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research report on Wednesday, November 22nd. Finally, Bank of America assumed coverage on ABLYNX in a research report on Friday, November 10th. They set a “buy” rating and a $26.00 price objective for the company.
Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.
Receive News & Ratings for ABLYNX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABLYNX and related companies with MarketBeat.com's FREE daily email newsletter.